AUS
NZ
UK
CA
USA
IND
Highlights
- Bioxyne (BXN) lifts FY25 revenue forecast to $28 million
- Demand surges for psychedelic-assisted therapy solutions
- Strategic manufacturing agreement supports multi-market expansion
Bioxyne (ASX:BXN), a diversified health and wellness company, has raised its full-year 2025 revenue outlook by $3 million to $28 million, driven by increased momentum in the pharmaceutical and psychedelic drug therapy sectors.
This revised guidance follows strong first-half results, with Bioxyne reporting $12.6 million in revenue—a 267% jump compared to the previous corresponding period. The company is forecasting an additional $15.4 million in the second half, marking a 226% uplift year-on-year.
Key Drivers Behind the Outlook Boost
The revenue upgrade is attributed to evolving pharmaceutical manufacturing trends in Australia and robust international demand, particularly in Germany and the UK. Bioxyne’s wholly owned subsidiary, Breathe Life Sciences, has played a central role in this growth. The subsidiary specializes in the development and manufacturing of medicinal cannabis, MDMA, and psilocybin therapies for clinical trials and authorized prescribers both locally and internationally.
Australia and Germany each represent billion-dollar opportunities annually, with the UK and other EU countries offering another $1 billion in high-growth market potential. Bioxyne operates across these regions within the rapidly expanding medical cannabis landscape, estimated to be worth over $3 billion annually by 2025.
Market Expansion and Product Development
Globally, the psychedelic drug market is forecast to reach $14 billion by 2032. Notably, therapies targeting post-traumatic stress disorder (PTSD) and treatment-resistant depression are expected to contribute $3.5 billion and $5 billion per year, respectively.
Bioxyne is aligning its product pipeline with these projections, advancing the development of MDMA capsule formulations BLSMD40 and BLSMD100. Commercial batch production is slated to begin in July, indicating a move toward scaled operations and broader market penetration.
Strengthening Supply Chain Through Strategic Agreements
To support this growth trajectory, Breathe Life Sciences has secured a $7 million manufacturing and supply agreement with NectarTek Australia. The 12-month contract outlines minimum order volumes across multiple product categories: $3.6 million in pastilles, $2.5 million in packed flower, and $500,000 each in vape and oral mucosal oil products. This agreement marks a 200% increase in orders compared to previous volumes.
With expanding domestic and international footprints and strong sector tailwinds, Bioxyne (BXN) is strategically positioned to capture rising demand for innovative, regulated psychedelic therapies.
